| (C) Means to Enhance Penetration:(4) Delivery systems for penetration enhancement of peptide and protein drugs: design considerations UB Kompella, VHL Lee Advanced drug delivery reviews 8 (1), 115-162, 1992 | 49 | 1992 |
| 16 Nanoparticles for the Treatment of Retinal Diseases A Famili, UB Kompella Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate …, 2012 | | 2012 |
| 17 Delivery of Peptide and Protein Drugs E Ha, M Ganguly, X Li, BR Jasti, UB Kompella CONTEMPORARY PHARMACEUTICS, 525, 2005 | | 2005 |
| 2021 JOPT Award in Science: Dr. Bärbel Rohrer's Research on Mitochondria-Targeted Neuroprotective Drugs UB Kompella Journal of Ocular Pharmacology and Therapeutics 38 (9), 591-591, 2022 | 1 | 2022 |
| 2nd Ophthalmic Drug Development and Delivery Summit: San Diego, CA, USA, 19–20 September 2006 M Marra, HJ Gukasyan, S Raghava, UB Kompella Expert Opinion on Drug Delivery 4 (1), 77-85, 2007 | 11 | 2007 |
| 4-Hydroxynonenal increases VEGF secretion from human retinal pigment epithelial (ARPE-19) cells by inducing oxidative stress and VEGF mRNA expression. U Kompella, S Ayalasomayajula INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 42 (4), S242-S242, 2001 | | 2001 |
| 489. Tumor-Targeted Hursirna-Nanoparticle Delivery Inhibits Lung Tumor Growth In Vitro and In Vivo R Muralidharan, N Amreddy, A Babu, A Srivastava, J Panneerselvam, ... Molecular Therapy 24, S194, 2016 | 1 | 2016 |
| 94 Stratagems for discovery of novel biologically active compounds with the efficient use of parallel chemistry A Kozikowski, AB Reitz, J Neres, RA Bryce, KT Douglas, JG Christie, ... | | |
| 969: DYSREGULATED MICRORNAS IN ACUTE LUNG INJURY: MIR-26A REGULATES LUNG ENDOTHELIAL CELL PERMEABILITY R Good, L Hernandez-Lagunas, K Swain, C Vohwinkel, C Sucharov, ... Critical Care Medicine 44 (12), 318, 2016 | | 2016 |
| A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for … JV Aukunuru, G Sunkara, SP Ayalasomayajula, J DeRuiter, RC Clark, ... Pharmaceutical research 19 (3), 278-285, 2002 | 41 | 2002 |
| A High-Throughput LC-MS/MS Method for the Simultaneous Quantification of Twenty-Seven Drug Molecules in Ocular Tissues B Matter, DWA Bourne, UB Kompella AAPS PharmSciTech 23 (6), 192, 2022 | 3 | 2022 |
| A Novel Dendrimer Formulation for Enhanced Solubility and Delivery of Gatifloxacin, Ketorolac Tromethamine, and Tropicamide C Durairaj, P Tyagi, J Chandler, U Kompella Investigative Ophthalmology & Visual Science 50 (13), 2421-2421, 2009 | | 2009 |
| A Pharmacodynamic Analysis of Choroidal Neovascularization in a Porcine Model J Tran, C Craven, K Wabner, J Schmit, UB Kompella, HE Grossniklaus, ... Investigative Ophthalmology & Visual Science 58 (8), 250-250, 2017 | | 2017 |
| A pharmacodynamic analysis of choroidal neovascularization in a porcine model using three targeted drugs J Tran, C Craven, K Wabner, J Schmit, B Matter, U Kompella, ... Investigative Ophthalmology & Visual Science 58 (9), 3732-3740, 2017 | 12 | 2017 |
| A57 LUNG INJURY, REPAIR, AND FIBROSIS: THE PLOT THICKENS FOR THREE'S COMPANY: Dysregulated Mirnas In Pediatric Ards And Animal Models Of Acute Lung Injury: Focus On Mir26a And … EN Grayck, C Sucharov, AL Hernandez, U Kompella, T Carpenter American Journal of Respiratory and Critical Care Medicine 191, 1, 2015 | | 2015 |
| Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells GC Baltazar, S Guha, W Lu, J Lim, K Boesze-Battaglia, AM Laties, P Tyagi, ... PloS one 7 (12), e49635, 2012 | 144 | 2012 |
| Acidic nanoparticles enhance degradative lysosomal enzyme activity in compromised RPE cells G Baltazar, S Guha, AM Laties, P Tyagi, UB Kompella, CH Mitchell Investigative Ophthalmology & Visual Science 52 (14), 3216-3216, 2011 | 1 | 2011 |
| Acidification of RPE Lysosomes by Nanoparticles G Baltazar, S Guha, AM Laties, UB Kompella, CH Mitchell Investigative Ophthalmology & Visual Science 51 (13), 700-700, 2010 | 1 | 2010 |
| Activation of liver X receptor prevents the development of severe pulmonary arterial hypertension L Tarasevičienė-Stewart, M Leberl, A Kratzer, J Salys, U Kompella, ... Respiratory and Critical Care Medicine: American Thoracic Society 2013 …, 2013 | | 2013 |
| Activation Of Liver X Receptor Prevents The Development Of Severe Pulmonary Arterial Hypertension L Taraseviciene-Stewart, M Leberl, A Kratzer, J Salys, U Kompella, ... C63. EXPERIMENTAL MODELS OF PULMONARY VASCULAR DISEASE I, A4643-A4643, 2013 | | 2013 |
